Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Curie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women with metastatic ductal adenocarcinoma breast cancer
18 years old or more
Hormone receptors positive breast cancer (ER+ and/or PR+) on the last pathological analysis available.
Acceptable patient's clinical situation compatible with chemotherapy or hormonotherapy administration
PS \<4
Life expectancy \> 3 months
Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before selection
Information of the patient and signature of the informed consent form
You may not be if
Patient treated by chemotherapy or hormonotherapy for their metastatic disease (treatment failure under adjuvant hormonotherapy are accepted)
Her2 positive breast cancer
History of other stage II or III cancer in the 5 years. History of other metastatic cancer (whatever the time between the two cancers).
Persons deprived of their freedom or under guardianship.
Women unable to comply with the medical follow-up of the study for geographical, social or mental reasons.
Clareo Health | Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
